ArticleMolecules (Basel, Switzerland)2026
Quality Comparative Evaluation of Eungyosan Formulations by a Validated HPLC-PDA Method for 11 Marker Components.
Article in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Eungyosan (EGS) is a traditional multi-herbal formulation widely used for the treatment of respiratory diseases; however, its quality control remains challenging due to its complex chemical composition. This study aimed to develop and validate a high-performance liquid chromatography coupled with photodiode array detection (HPLC-PDA) method for simultaneous determination of 11 representative marker compounds in EGS and to apply the method to the comparative quality evaluation of laboratory-prepared and commercial EGS formulations. Chromatographic conditions were optimized, and the marker compounds were selected based on their herbal origin, phytochemical relevance, and chromatographic detectability. The method was validated in terms of linearity, sensitivity (limits of detection and quantification), precision, accuracy, and stability. All analytes exhibited excellent linearity (coefficient of determination > 0.9999), along with satisfactory precision (relative standard deviation < 2%) and recovery (95.64-105.69%). The validated method was successfully applied to a laboratory-prepared extract and three commercial granule formulations. Considerable differences in the levels of marker compounds were observed among the samples; several marker compounds were either not detected or could not be quantified because of UV spectral mismatch in certain commercial products. These findings demonstrate variability in the chemical composition of the tested EGS formulations and highlight the usefulness of the validated HPLC-PDA method for comparative quality evaluation of multi-herbal formulations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.